FLT3 ITD

CI-VAR-00002037Explore in graph →ClinVar 16270 CIViC 55

Curated evidence

Evidence by cancer (52 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 51–52 of 52 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
FLT3 ITD AND ( FLT3 Y842C OR FLT3 Y842H )	Quizartinib	Predictive	D	Supports Resistance	3	submitted	EID12628 In an in-vitro study using an in vitro saturation mutagenesis assay, residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified, including Y842C… (full text at CIViC) PMID 22504184 · Smith et al., 2012 · Open in CIViC	civic
Myelodysplastic Syndrome1
FLT3 ITD	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID12429 This study reports the effect of FLT3-ITD mutations on the rate of progression of MDS to AML and on a patient's overall survival. The study cohort consisted of 82 MDS patients, with paired samples ana… (full text at CIViC) PMID 14737077 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.